Back to Results


Title A Study to evaluate the efficacy and safety of VX-147 in Subjects with APOL1-mediated Proteinuric Kidney Disease
Therapeutic Area Chronic Kidney Disease, Nephropathy, Proteinuria
Principal Investigator Daniel Weiner, MD, MS
Min Age 18 Years
Max Age 60 Years
Gender Any
More Information


A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease

Study Details

Inclusion Criteria

1. Age 18-60

2. Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex-designated investigational clinical study assay.

Exclusion Criteria

1. History of organ / bone marrow transplantation

2. Diagnosis of Diabetes Mellitus

3. History of human immunodeficiency virus (HIV), hepatitis B (HBV) infection, or hepatitis C (HCV) infection.


If you aren't sure if you qualify, please call us and we will help determine your eligibility. 

Study Requirements

This study will last approximately 2 years. Patients will have visits approximateley every 4 weeks, blood drawn, ECGs taken, and vitals taken. Home health visits available.